1263378-40-0

Basic information

• Product Name: 2-Chloro-3-fluoro-6-methoxybenzaldehyde
• Synonyms: 2-Chloro-3-fluoro-6-methoxybenzaldehyde
• CAS NO: 1263378-40-0
• Molecular Formula: C₈H₆ClFO₂
• Molecular Weight: 188.5834432
• Mol File: 1263378-40-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Chloro-3-fluoro-6-methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-fluoro-6-methoxybenzaldehyde(1263378-40-0)
• EPA Substance Registry System: 2-Chloro-3-fluoro-6-methoxybenzaldehyde(1263378-40-0)

Safety Data

• Hazardous Substances Data: 1263378-40-0(Hazardous Substances Data)

Upstream product

• 261762-39-4 2-chloro-3,6-difluorobenzaldehyde 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 
• 107-31-3 Methyl formate 
• 202925-07-3 2-chloro-1-fluoro-4-methoxybenzene 

Downstream Products

• 1350322-49-4 5-bromo-3-[(2-chloro-3-fluoro-6-methoxyphenyl)-hydroxymethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1350324-09-2 (2R)-3-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-3,5-dimethyl-1H-pyrazol-1-yl]propane-1,2-diol 
• 1350325-59-5 (2S)-3-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methyl-1H-pyrazol-1-yl]propane-1,2-diol 
• 1350324-23-0 trans-4-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methyl-1H-pyrazol-1-yl]cyclohexanol 
• 1350324-33-2 trans-4-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methyl-1H-pyrazol-1-yl]cyclohexanecarboxamide 
• 1350425-10-3 (2R)-3-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methyl-1H-pyrazol-1-yl]propane-1,2-diol 
• 1350324-83-2 3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-5-[5-methyl-1-(piperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridine 
• 1350324-91-2 1-{4-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methyl-1H-pyrazol-1-yl]piperidin-1-yl}ethanone 
• 1350325-01-7 trans-4-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-3-methoxy-1H-pyrazol-1-yl]cyclohexanol 
• 1350322-46-1 5-bromo-3-[1-(2-chloro-3-fluoro-6-methoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridine 
• 1350322-56-3 2-Chloro-6-difluoromethoxy-3-fluorobenzaldehyde 
• 1350322-55-2 2-chloro-4-difluoromethoxy-3-dimethoxymethyl-1-fluorobenzene 
• 1350322-57-4 3-chloro-2-dimethoxymethyl-4-fluorophenol 
• 1350322-58-5 3-[(1S)-1-(2-Chloro-3-fluoro-6-methoxyphenyl)ethyl]-5-(3-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activ

CYCLOPROPYLMETHANAMINES AS SELECTIVE 5-HT(2C) RECEPTOR AGONISTS

Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.

N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS,

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicat

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models

A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists. Compound (+)-22a was identified as a potent

FUSED BICYCLIC KINASE INHIBITORS

Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention.

Fused Bicyclic Kinase Inhibitors

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

FUSED BICYCLIC KINASE INHIBITORS

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as but not limited to tumors driven at least in part by at least one of RON, MET, IR, IGF-1 R, or ALK. This Abstract is not limiting of the invention.